Quantitative Systems Pharmacology: A Case for Disease Models
Copyright policy )Quantitative Systems Pharmacology: A Case for Disease Models
Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model‐informed drug discovery and development, supporting program decisions from exploratory research through late‐stage clinical trials. In this commentary, we discuss the unique value of disease‐scale “platform” QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.
- GENENTECH INC United States
- AstraZeneca (United Kingdom) United Kingdom
- PFIZER INC United States
- Bristol-Myers Squibb (Germany) Germany
- Pfizer (United States) United States
Clinical Trials as Topic, Biomedical Research, Systems Biology, Decision Making, Models, Biological, Drug Design, Drug Discovery, Pharmacology, Clinical, Humans, Perspectives
Clinical Trials as Topic, Biomedical Research, Systems Biology, Decision Making, Models, Biological, Drug Design, Drug Discovery, Pharmacology, Clinical, Humans, Perspectives
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).65 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!